Primary results of the brazilian registry of atherothrombotic disease (NEAT)
Pedro G. M. de Barros e Silva,Charlene Troiani do Nascimento,Rodrigo Pinto Pedrosa,Marcelo Arruda Nakazone,Michel Ulloffo do Nascimento,Leiliandry de Araújo Melo,Osvaldo Lourenço Silva Júnior,Sérgio Luiz Zimmermann,Rodrigo Morel Vieira de Melo,Ricardo Reinaldo Bergo,Dalton Bertolim Precoma,Lucas Tramujas,Eduardo Gomes Lima,João Miguel Malta Dantas,Antônio Cláudio do Amaral Baruzzi,Ronald Luiz Gomes Flumignan,Maria Sanali Moura de Oliveira Paiva,Luís Henrique Wolff Gowdak,Priscila Nasser de Carvalho,José Albuquerque de Figueiredo Neto,Odilson Marcos Silvestre,Alexandre Fioranelli,Ricardo D.’Oliveira Vieira,Ana Clara Peneluppi Horak,Debora Harumi Kodama Miyada,Flávia Cristina Soares Kojima,Júlia Souza de Oliveira,Leila de Oliveira Silva,Ricardo Pavanello,Eduardo Ramacciotti,Renato D. Lopes,Ricardo D.'Oliveira Vieira,Ricardo D.'Oliveira Vieira,José Augusto Ribas Fortes,Luiz Eduardo Fonteles Ritt,Lúcio R. Requião-Moura,Fabricio Assami Borges,Claudia Bernoche,Mauricio Antonio Pompilio,the NEAT Investigators
DOI: https://doi.org/10.1038/s41598-024-54516-9
IF: 4.6
2024-02-21
Scientific Reports
Abstract:There is limited contemporary prospective real-world evidence of patients with chronic arterial disease in Latin America. The Network to control atherothrombosis (NEAT) registry is a national prospective observational study of patients with known coronary (CAD) and/or peripheral arterial disease (PAD) in Brazil. A total of 2,005 patients were enrolled among 25 sites from September 2020 to March 2022. Patient characteristics, medications and laboratorial data were collected. Primary objective was to assess the proportion of patients who, at the initial visit, were in accordance with good medical practices (domains) for reducing cardiovascular risk in atherothrombotic disease. From the total of patients enrolled, 2 were excluded since they did not meet eligibility criteria. Among the 2,003 subjects included in the analysis, 55.6% had isolated CAD, 28.7% exclusive PAD and 15.7% had both diagnoses. Overall mean age was 66.3 (± 10.5) years and 65.7% were male patients. Regarding evidence-based therapies (EBTs), 4% were not using any antithrombotic drug and only 1.5% were using vascular dose of rivaroxaban (2.5 mg bid). Only 0.3% of the patients satisfied all the domains of secondary prevention, including prescription of EBTs and targets of body-mass index, blood pressure, LDL-cholesterol, and adherence of lifestyle recommendations. The main barrier for prescription of EBTs was medical judgement. Our findings highlight that the contemporary practice does not reflect a comprehensive approach for secondary prevention and had very low incorporation of new therapies in Brazil. Large-scale populational interventions addressing these gaps are warranted to improve the use of evidence-based therapies and reduce the burden of atherothrombotic disease.
multidisciplinary sciences